Bio-heart Confirms Stable Share Capital and Sufficient Public Float in April 2026 Monthly Return

Bulletin Express

05/06

Shanghai Bio-heart Biological Technology Co., Ltd. (Bio-heart) reported no movements in share capital for the month ended 30 April 2026, according to its Monthly Return filed on 6 May 2026 with the Hong Kong Stock Exchange.

The authorised and issued H-share capital stood unchanged at 235.70 million shares with a par value of RMB 1 each. Unlisted foreign shares also remained steady at 7.71 million shares. Consequently, total authorised share capital stayed at RMB 243.42 million.

No shares were issued, repurchased, cancelled or held in treasury during the period. Bio-heart confirmed compliance with the Main Board’s minimum 25% public-float requirement.

The company reported no outstanding share options, warrants, convertibles or other equity-linked instruments. The filing was signed by Executive Director and Joint Company Secretary Wang Yuqing.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1165791757"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1165791757\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1165791757?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 17:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165791757","market":"hk","top_or_hot":-1,"title":"Bio-heart Confirms Stable Share Capital and Sufficient Public Float in April 2026 Monthly Return","media":"Bulletin Express","content":"<p>Shanghai Bio-heart Biological Technology Co., Ltd. (Bio-heart) reported no movements in share capital for the month ended 30 April 2026, according to its Monthly Return filed on 6 May 2026 with the Hong Kong Stock Exchange.</p>\n<p>The authorised and issued H-share capital stood unchanged at 235.70 million shares with a par value of RMB 1 each. Unlisted foreign shares also remained steady at 7.71 million shares. Consequently, total authorised share capital stayed at RMB 243.42 million.</p>\n<p>No shares were issued, repurchased, cancelled or held in treasury during the period. Bio-heart confirmed compliance with the Main Board’s minimum 25% public-float requirement.</p>\n<p>The company reported no outstanding share options, warrants, convertibles or other equity-linked instruments. The filing was signed by Executive Director and Joint Company Secretary Wang Yuqing.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bio-heart Confirms Stable Share Capital and Sufficient Public Float in April 2026 Monthly Return</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBio-heart Confirms Stable Share Capital and Sufficient Public Float in April 2026 Monthly Return\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-06 17:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Bio-heart Biological Technology Co., Ltd. (Bio-heart) reported no movements in share capital for the month ended 30 April 2026, according to its Monthly Return filed on 6 May 2026 with the Hong Kong Stock Exchange.</p>\n<p>The authorised and issued H-share capital stood unchanged at 235.70 million shares with a par value of RMB 1 each. Unlisted foreign shares also remained steady at 7.71 million shares. Consequently, total authorised share capital stayed at RMB 243.42 million.</p>\n<p>No shares were issued, repurchased, cancelled or held in treasury during the period. Bio-heart confirmed compliance with the Main Board’s minimum 25% public-float requirement.</p>\n<p>The company reported no outstanding share options, warrants, convertibles or other equity-linked instruments. The filing was signed by Executive Director and Joint Company Secretary Wang Yuqing.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02185","symbol_name":"百心安-B","start_time":0,"source_url":"","article_id":"1165791757","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165791757","pubTimestamp":1778059409,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Bio-heart Biological Technology Co., Ltd. (Bio-heart) reported no movements in share capital for the month ended 30 April 2026, according to its Monthly Return filed on 6 May 2026 with the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02185":"百心安-B"},"translate_title":"Bio-heart确认2026年4月股本稳定及公众持股量充足月报表","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02185":1},"content_text":"Shanghai Bio-heart Biological Technology Co., Ltd. (Bio-heart) reported no movements in share capital for the month ended 30 April 2026, according to its Monthly Return filed on 6 May 2026 with the Hong Kong Stock Exchange.\nThe authorised and issued H-share capital stood unchanged at 235.70 million shares with a par value of RMB 1 each. Unlisted foreign shares also remained steady at 7.71 million shares. Consequently, total authorised share capital stayed at RMB 243.42 million.\nNo shares were issued, repurchased, cancelled or held in treasury during the period. Bio-heart confirmed compliance with the Main Board’s minimum 25% public-float requirement.\nThe company reported no outstanding share options, warrants, convertibles or other equity-linked instruments. The filing was signed by Executive Director and Joint Company Secretary Wang Yuqing.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}